Epilepsy Care in Transgender Patients
Authors:
- 6 June 2022
- journal article
- review article
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 22 (8) , 451-458
Abstract
Purpose of Review The goal of this review is to outline the main considerations when treating transgender patients with epilepsy. Points to be addressed include the gender affirming hormone therapy regimens and how they interact with anti-seizure medications and seizure control, as well as common co-morbidities in the transgender epilepsy population. Recent Findings Gender affirming hormone therapy (GAHT) may affect seizure control directly, due to proconvulsant or anticonvulsant properties. GAHT may interact with anti-seizure medications; most notably, estrogen will decrease serum concentration of lamotrigine. Enzyme-inducing anti-seizure medications may decrease hormone levels, potentially interfering with goals of GAHT. Transgender epilepsy patients are at risk for co-morbidities such as decreased bone mineral density and depression. Summary There are minimal direct studies on treatment or outcomes in the transgender epilepsy population. Providers must be knowledgeable about the bi-directional interactions between gender affirming hormone therapy and anti-seizure medications, as well as direct hormonal influences on seizure control. Future research should directly evaluate outcomes in transgender epilepsy patients with regard to seizure control, success of hormone therapy, and management of co-morbidities, to further educate providers and patients how to best manage their healthcare.Keywords
This publication has 41 references indexed in Scilit:
- Sex and hormonal influences on seizures and epilepsyHormones and Behavior, 2013
- Epilepsy, suicidality, and psychiatric disorders: A bidirectional associationAnnals of Neurology, 2012
- Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDSNeurology, 2012
- Antiepileptic drug selection for people with HIV/AIDS: Evidence‐based guidelines from the ILAE and AANEpilepsia, 2012
- Effect of levetiracetam on testosterone levels in male patientsEpilepsia, 2010
- The Testosterone-Derived Neurosteroid Androstanediol Is a Positive Allosteric Modulator of GABAA ReceptorsThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive useNeurology, 2009
- Neuroactive steroids and seizure susceptibilityEpilepsy Research, 2001
- Effects of hormone deficiency, androgen therapy and calcium supplementation on bone mineral density in female transsexualsMaturitas, 1997
- Polycystic Ovaries and Hyperandrogenism in Women Taking Valproate for EpilepsyNew England Journal of Medicine, 1993